Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd Ads (NQ: BGNE )

320.00 USD -9.73 (-2.95%)
Official Closing Price Updated: 4:31 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 397,200
Open 314.56
Bid (Size) 314.00 (1)
Ask (Size) 322.00 (1)
Prev. Close 329.73
Today's Range 313.26 - 327.21
52wk Range 118.55 - 388.97
Shares Outstanding 53,760,296
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
BeiGene Announces Closing of Collaboration with Novartis to Develop & Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan 
From Business Wire News Releases
BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights,... 
From Business Wire News Releases

Performance

YTD
+22.60%
+22.60%
1 Month
+0.51%
+0.51%
3 Month
+25.15%
+25.15%
6 Month
+32.47%
+32.47%
1 Year
+102.08%
+102.08%

More News

Read More
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
From Business Wire News Releases
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia
From Business Wire News Releases
Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy
Tags Hepatits A BGNE Market News
From Benzinga
BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
From Business Wire News Releases
BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review
Tags FDA General Biotech
From Benzinga
Stocks Showing Improving Market Leadership: Beigene Earns 84 RS Rating
From Investor's Business Daily
Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor
Tags Market News Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
bye bye BGNE and Mexichem
Tags Stocks / Equities
From Blogs - TalkMarkets
Stock Squeeze Remnants
Tags Stocks / Equities
From Blogs - TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.